JP Morgan Chase’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-292,931
| Closed | -$8.2M | – | 7208 |
|
|
2022
Q1 | $8.2M | Buy |
292,931
+4,382
| +2% | +$120K | ﹤0.01% | 2573 |
|
|
2021
Q4 | $7.88M | Sell |
288,549
-60,042
| -17% | -$1.63M | ﹤0.01% | 2661 |
|
|
2021
Q3 | $9.48M | Buy |
348,591
+285,038
| +449% | +$7.05M | ﹤0.01% | 2427 |
|
|
2021
Q2 | $1.09M | Sell |
63,553
-219,986
| -78% | -$4.12M | ﹤0.01% | 4235 |
|
|
2021
Q1 | $5.92M | Sell |
283,539
-57,970
| -17% | -$1.34M | ﹤0.01% | 2824 |
|
|
2020
Q4 | $7.82M | Sell |
341,509
-61,500
| -15% | -$1.17M | ﹤0.01% | 2408 |
|
|
2020
Q3 | $6.63M | Buy |
403,009
+5,723
| +1% | +$104K | ﹤0.01% | 2341 |
|
|
2020
Q2 | $5.38M | Buy |
397,286
+58,012
| +17% | +$675K | ﹤0.01% | 2402 |
|
|
2020
Q1 | $4.02M | Buy |
339,274
+325,912
| +2,439% | +$7.23M | ﹤0.01% | 2450 |
|
|
2019
Q4 | $333K | Buy |
13,362
+952
| +8% | +$19.3K | ﹤0.01% | 4454 |
|
|
2019
Q3 | $211K | Sell |
12,410
-12,520
| -50% | -$228K | ﹤0.01% | 4611 |
|
|
2019
Q2 | $568K | Sell |
24,930
-7,757
| -24% | -$209K | ﹤0.01% | 4177 |
|
|
2019
Q1 | $1.05M | Buy |
32,687
+2,493
| +8% | +$77.1K | ﹤0.01% | 3783 |
|
|
2018
Q4 | $850K | Buy |
30,194
+19,167
| +174% | +$561K | ﹤0.01% | 3846 |
|
|
2018
Q3 | $317K | Sell |
11,027
-841
| -7% | -$25.3K | ﹤0.01% | 4504 |
|
|
2018
Q2 | $444K | Buy |
11,868
+5,250
| +79% | +$206K | ﹤0.01% | 4227 |
|
|
2018
Q1 | $259K | Buy |
6,618
+798
| +14% | +$29.1K | ﹤0.01% | 4277 |
|
|
2017
Q4 | $189K | Buy |
5,820
+5,524
| +1,866% | +$166K | ﹤0.01% | 4436 |
|
|
2017
Q3 | $9K | Sell |
296
-75,336
| -100% | -$2.23M | ﹤0.01% | 4740 |
|
|
2017
Q2 | $2.11M | Buy |
75,632
+65,138
| +621% | +$1.47M | ﹤0.01% | 3009 |
|
|
2017
Q1 | $180K | Sell |
10,494
-18,178
| -63% | -$255K | ﹤0.01% | 4110 |
|
|
2016
Q4 | $347K | Sell |
28,672
-95,076
| -77% | -$1.23M | ﹤0.01% | 3928 |
|
|
2016
Q3 | $1.96M | Sell |
123,748
-22,901
| -16% | -$345K | ﹤0.01% | 2814 |
|
|
2016
Q2 | $1.9M | Sell |
146,649
-15,135
| -9% | -$237K | ﹤0.01% | 2838 |
|
|
2016
Q1 | $3.07M | Sell |
161,784
-12,070
| -7% | -$219K | ﹤0.01% | 2478 |
|
|
2015
Q4 | $3.91M | Sell |
173,854
-104,233
| -37% | -$2.06M | ﹤0.01% | 2373 |
|
|
2015
Q3 | $6.51M | Buy |
278,087
+88,345
| +47% | +$2.44M | ﹤0.01% | 2058 |
|
|
2015
Q2 | $5.43M | Sell |
189,742
-104,098
| -35% | -$2.73M | ﹤0.01% | 2340 |
|
|
2015
Q1 | $7.59M | Buy |
293,840
+272,264
| +1,262% | +$6.23M | ﹤0.01% | 2073 |
|
|
2014
Q4 | $400K | Sell |
21,576
-74,596
| -78% | -$1.34M | ﹤0.01% | 3763 |
|
|
2014
Q3 | $1.49M | Buy |
+96,172
| New | +$1.45M | ﹤0.01% | 3106 |
|
JP Morgan Chase's XENT Position: Q2 2022 in Review
JP Morgan Chase sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 292,931 shares — an estimated $8.2M sold.
JP Morgan Chase first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $9.48M in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- JP Morgan Chase reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- JP Morgan Chase sold 292,931 Intersect ENT, Inc shares in Q2 2022, an estimated $8.2M.
- JP Morgan Chase first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
- JP Morgan Chase's Intersect ENT, Inc position peaked at $9.48M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.